Pre-market hot trades in US stocks: Eightco up 9.68% in pre-market; PDS Biotechnology down 9.38% in pre-market

Pre-market Hot Trades in US Stocks Eightco is up 9.68% in pre-market trading. Based on recent key news: On April 16, Eightco Holdings confirmed it holds 277 million WLD tokens, accounting for about 9% of the circulating supply, and has a stake in OpenAI valued at $90 million. This move solidifies Eightco's position in the cryptocurrency space and drives the stock price up. On April 16, Eightco board member Tom Lee and CEO Kevin O’Donnell plan to attend the World Lift Off event on April 17 to support the adoption of the Proof-of-Human protocol. This news boosts market confidence in Eightco, further driving the stock price up. On April 16, Eightco continues to be the largest public holder of Worldcoin tokens, further consolidating its influence in the cryptocurrency space. This news has a positive impact on the stock price. The cryptocurrency market is experiencing increased volatility, caution is advised. PDS Biotechnology is down 9.38% in pre-market trading. Based on recent key news: On April 15, PDS Biotechnology announced that its experimental drug PDS01ADC showed strong responses in a mid-stage study for metastatic colorectal cancer, with about 78% of patients responding to treatment and approximately 85% surviving after two years. This news drove the stock price up. On April 15, PDS Biotechnology announced that its PDS01ADC drug achieved positive mid-stage data in an NCI-led trial for metastatic colorectal cancer, showing a 77.8% objective response rate and about 85% 24-month survival rate. This news further supports the stock price increase. On April 16, PDS Biotechnology presented early positive results of its drug PDS01ADC at the AACR Prostate Cancer Research Special Meeting, showing a median progression-free survival of 9.6 months and a 40% median PSA decline. This news has a positive impact on the stock price. The biotechnology sector has been active recently, with significant capital inflows. Top Gainers in Pre-market US Stocks Psyence Biomedical is up 94.38% in pre-market trading. Based on recent key news: On April 15, Psyence Biomedical announced it aims to accelerate patient recruitment, improve operational efficiency, and strengthen its position in the emerging psychedelic clinical space by increasing experienced hospital and specialized research partnerships and supplying NPX-5 from its GMP-certified facility. This news significantly boosted the stock price. Source: Reuters Recently, there are no other important related news. The attention on the psychedelic drug sector is rising, and market volatility is increasing. YXT.COM, pre-market up 63.76%, no important news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Able View Global, pre-market up 46.55%, no important news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation